Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results Inhibrx (Nasdaq: INBX) reported fourth quarter and fiscal 2025 results on March 19, 2026, highlighting clinical milestones and financials. Cash and cash equivalents were $124.2 million as of December 31, 2025, and the company obtained $75.0 million in loan proceeds on March 18, 2026.Fiscal 2025 R&D expense was $113.0 million versus $203.7 million in 2024; net loss was $140.1 million for fiscal 2025 versus net income of $1.7 billion in fiscal 2024. Key clinical milestones and trial data readouts are scheduled across 2026, including a planned BLA submission early Q2 2026 for ozekibart.

#INBX Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

www.stocktitan.net/news/INBX/inhibrx-report...

Breaking News: ( NASDAQ: #INBX ) Market Perform Recommendation Issued On INBX By Citigroup

NEWS: ( NASDAQ: #INBX ) Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program SAN DIEGO, Dec. 16, 2025/ PRNewswire/-- Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/ 3 clinical trial in combination with Keytruda ® as a first-line treatment for patients with locally advanced unresectable or metastatic head and...

#INBX Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

www.stocktitan.net/news/INBX/inhibrx-biosci...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#HUT, #ALT, #CRML, #AEVA, #INBX

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #INBX ) Inhibrx Reports Third Quarter 2025 Financial Results

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#INBX, #OMC, #APLD, #WM, #SAN

#OptionFlow #OptionsTrading #Trading

Inhibrx Reports Third Quarter 2025 Financial Results Inhibrx (Nasdaq: INBX) reported third quarter 2025 results and clinical updates on November 14, 2025. Ozekibart (INBRX-109) met the registrational trial primary endpoint in chondrosarcoma with a statistically significant improvement in median progression-free survival versus placebo; key secondaries showed improved disease control and quality of life. The company plans to submit a BLA in Q2 2026. Interim expansion-cohort data show high response and disease control rates in colorectal cancer and Ewing sarcoma.Financials: cash and cash equivalents were $153.1M as of September 30, 2025 (down from $186.6M on June 30, 2025). R&D expense was $28.5M and G&A was $5.3M for Q3 2025. Net loss was $35.3M or $2.28 per share.

#INBX Inhibrx Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/INBX/inhibrx-report...

He bought it after a +138% run.

Days later, the company announced positive Phase II cancer results.

Andreas Halvorsen put $3.7M into Inhibrx Biosciences at $33.50.

Now worth $8.1M.
Up +136% in a month.

What did he know?

$INBX #STOCKS #INBX

Just In: ( NASDAQ: #INBX ) Inhibrx Announces Participation in Upcoming Scientific Conferences

Andreas Halvorsen just bought a stock that is up +138% YTD.

This trade was executed only 8-days ago.

• Inhibrx Biosciences – $3.7M (+7% return)

He’s adding at these levels? Wtf.

$INBX #INBX #Stocks #Investing

Inhibrx Reports Second Quarter 2025 Financial Results and Future Milestones Inhibrx Biosciences, Inc. announces its financial results for Q2 2025, detailing revenue growth and pipeline updates, projecting exciting future clinical trial data.

Inhibrx Reports Second Quarter 2025 Financial Results and Future Milestones #USA #San_Diego #Clinical_Trials #Inhibrx_Biosciences #INBX

Inhibrx Q2 Results: $186M Cash Runway as Two Major Cancer Drug Trials Near Data Readouts Biotech firm reports Q2 loss while maintaining $186.6M cash position. Pivotal cancer drug trial data expected by October for chondrosarcoma treatment. Get pipeline insights.

#INBX Inhibrx Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/INBX/inhibrx-report...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks overbought with declining relative strength, Mon Jul 21st - #GSIW #RILY #ONCY #INDI #INBX #FDUS #ENVX #BWEN #ZK - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Wed Jul 9th - #XLO #TAOX #SBC #RAIL #PAHC #OABI #KALA #INBX #GSIT #CNXN #AZTA #LDI #GGT #DK #CPUH #BGR #ALUR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Inhibrx Slashes Q1 Losses by 45%, Reveals Multiple Clinical Trial Readouts Coming in 2025 Inhibrx reports improved financials with $216.5M cash position. Key trial data expected in H2 2025 for cancer programs. See full pipeline milestones.

#INBX Inhibrx Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/INBX/inhibrx-report...

Major Leadership Shake-up at Inhibrx: New CSO Takes Helm After $2.2B Sanofi Victory Internal promotions strengthen Inhibrx leadership team as co-founder departs. Strategic licensing deal and recent $2.2B Sanofi transaction signal promising future.

#INBX Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

www.stocktitan.net/news/INBX/inhibrx-biosci...

Inhibrx Reports Strong Financial Results for Q4 and Fiscal Year 2024 Inhibrx Biosciences, Inc. shares updates on their financial performance for the fourth quarter and fiscal year 2024, highlighting pivotal developments.

Inhibrx Reports Strong Financial Results for Q4 and Fiscal Year 2024 #United_States #San_Diego #Inhibrx #INBX #ozekibart

Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit Inhibrx reports $47.9M Q4 loss while achieving $1.7B annual profit. Ozekibart cancer trial shows promising results with complete response in colorectal cancer patient. $230.5M cash position.

#INBX Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

www.stocktitan.net/news/INBX/inhibrx-report...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Tue Mar 11th - #UFCS #ZVRA #RGR #TSVT #SLRN #RANI #QURE #PFC #MMLP #INBX #CRVO #BLTE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Inhibrx's Ozekibart Shows Promising 40% Response Rate in Advanced Colorectal Cancer Trial Preliminary Phase 1 data reveals complete response in one patient and partial responses in three others. Study demonstrates 7.85-month median progression-free survival with manageable safety profile.

#INBX Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

www.stocktitan.net/news/INBX/inhibrx-biosci...

Inhibrx Secures $150M Financing Deal to Advance Clinical Programs, Receives $100M Upfront Biotech firm Inhibrx lands major financing agreement with Oxford Finance, featuring $100M immediate funding and $50M available, supporting key clinical trials through 2025.

#INBX Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

www.stocktitan.net/news/INBX/inhibrx-biosci...

#INBX Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/INBX/inhibrx-biosci...